Editor's note: Seeking Alpha is proud to welcome Sergio Gonzalez as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. I am a corporate strategy professional with work experience across industrials, energy, and technology. My primary investment interest is in biotech where I have over a decade of investment experience. My secondary investment interests are ...

Some tickers are covered more than others on the site, so with The Undercovered Dozen our Editors highlight twelve actionable investment ideas on tickers with less coverage. These ideas can range from "boring" large caps to promising up-and-coming small caps. Specifically, the inclusion criteria for "undercovered" include: market cap greater than $100 million, more than 800 symbol page views in the last 90 days on Seeking Alpha, and fewer than two articles published in the past 30 days. Follow this account ...

BERKELEY HEIGHTS, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced new hospital admission and health economic data presented at the American Society of Nephrology Kidney Week 2024 in San Diego, CA from October 24 - 27. This retrospective analysis, using data from the Premier Healthcare Database, evaluated hospital admissions from 2020 to 2022 to examine th ...

BERKELEY HEIGHTS, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for lifethreatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2024, before the market opens on Wednesday, October 30, 2024, and will host a corporate update conference call at 8:30am Eastern Time. | --- | --- | |----------------|--------------------- ...

Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases [3] - The company is commercializing its lead product DefenCath®, which received FDA approval on November 15, 2023 [3] - DefenCath was launched in inpatient settings in April 2024 and in outpatient settings in July 2024 [3] Upcoming Events - Management will participate in a fireside chat and investor meetings at the 2024 Cantor Healthcare Conference in New York from September 17 to 19, 2024 [1] - The fireside chat is scheduled for September 19, 2024, at 10:55 AM EDT [2] - A replay of the fireside chat will be available on the investor relations section of the company's website [2]

Shares of CorMedix (CRMD) have been struggling lately and have lost 7.7% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road. The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the s ...

BERKELEY HEIGHTS, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a multi-year commercial supply contract with a global healthcare company for the supply of DefenCath® (taurolidine and heparin) to its facilities in the US. The company, which provides healthcare services to more than 2,000 clinics in the United States, expects to ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Eve ...

CorMedix (CRMD) closed the last trading session at $5.74, gaining 45.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $12.50 indicates an 117.8% upside potential. The mean estimate comprises four short-term price targets with a standard deviation of $4.51. While the lowest estimate of $9 indicates a 56.8% increase from the current price level, the most optimistic analyst expects ...

CorMedix (CRMD) closed the last trading session at $5.16, gaining 8.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $12.50 indicates a 142.3% upside potential. The mean estimate comprises four short-term price targets with a standard deviation of $4.51. While the lowest estimate of $9 indicates a 74.4% increase from the current price level, the most optimistic analyst expects th ...